Transcranial magnetic stimulation (TMS) has emerged as a major tool used in the field of noninvasive brain stimulation. TMS operates on Faraday’s principle of electromagnetic induction by which the transmission of a large, brief pulse of current through loops of copper wire (i.e., magnetic coil) give rise to a fluctuating magnetic field perpendicular to the plane of the coil that subsequently induces an electric field predominantly parallel to the inner surface of the volume.
conductor adjacent to the coil. In this way, the magnetic field is used to penetrate scalp and skull, while the electric field generates secondary currents leading to neuronal activation in the brain.\textsuperscript{1-4} TMS is capable of noninvasively stimulating a predetermined portion of the neuraxis and of temporarily modulating neuronal excitability (i.e., enhancing or suppressing this) at that site.\textsuperscript{3,4}

The expanding adoption of TMS into neuroscience research is reflected in the striking increase in PubMed publications when searching for transcranial magnetic stimulation: from 67 in 1990 to 1,488 in 2000 to 8,699 in 2012. In addition, there has been a commensurately large increase in the use of TMS both diagnostically and therapeutically. The US Food and Drug Administration (FDA) has cleared 2 TMS devices for psychiatric applications. The NeuroStar TMS Therapy system (Neurotechne, Malvern, PA) and, more recently, the Brainsway Deep TMS system (Jerusalem, Israel) have been cleared by the FDA for the treatment of medication-refractory depression. The growing therapeutic effect of TMS upon psychiatric practice is exemplified by the fact that hundreds of clinics in the United States now use an FDA-approved TMS system to treat depression.

In neurology, the Nexstim eXimia Navigated Brain System TMS device (Nexstim Oy, Helsinki, Finland) has FDA approval for presurgical motor and language mapping. The efficacy of TMS as a diagnostic or therapeutic tool in other neurologic contexts has yet to be confirmed. Nevertheless, a growing body of experimental work suggests that the clinical applicability of TMS in neurology, both as a diagnostic instrument and as a means of inducing changes in neural processing to achieve therapeutic gains, may soon be further expanded. This review will focus on mechanisms of action of TMS. It will then survey data from studies that suggest possible clinical applications of the methodology to neurology, while clearly delineating which of these applications have and have not been FDA approved.

**Methods of TMS application**

TMS can be applied as single pulses, as a pair of pulses (paired-pulse TMS) separated by a given interstimulus interval (ISI) and applied to the same or different brain areas, or as repetitive trains of stimulation (rTMS).\textsuperscript{3,4} Different forms of TMS application are schematically depicted in figure e-1. Single-pulse TMS is commonly applied over the primary motor cortex to activate contralateral muscles, a process that can be electrophysiologically recorded as motor evoked potentials (MEPs). These MEPs provide quantifiable attributes such as motor threshold for activation, signal amplitude, and latency, which can be correlated with cortical and corticospinal excitability.\textsuperscript{3,4} Physiologically, depending on the orientation of the TMS coil held over the scalp, TMS is thought to primarily exert its influence on corticospinal excitability through its effects upon synaptic transmission (which are reflected as indirect waves [I waves] in the MEP), or to more closely match the effects of transcranial electrical stimulation (TES) (which directly stimulates axons of descending motor pathways and which are reflected as direct waves [D waves] in the MEP).\textsuperscript{3,5} Paired-pulse TMS further allows for the assessment of more cortical-specific excitability.\textsuperscript{3}

Following repetitive TMS (rTMS), neuronal excitability can be altered for a sustained period that outlasts the time of stimulation. Depending on the parameters of rTMS applied, this excitability can be facilitated or suppressed.\textsuperscript{3,4} Moreover, the effects of TMS propagate transsynaptically to networks of regions anatomical and functionally connected to the stimulation site.\textsuperscript{4,6} The neurobiologic substrates of the effect of TMS remain insufficiently understood, but human and animal experiments are providing valuable insights. For example, acute effects of TMS appear to involve shifts in the ionic equilibrium around cortical neurons or the storage of charge directly from stimulation.\textsuperscript{4} More lasting effects seem to involve distributed brain network impacts, changes in oscillatory activity, specific neurochemical releases, and use-dependent mechanisms of plasticity, including synaptic modifications.\textsuperscript{4}

TMS can sometimes be associated with mild transient headache or mild neck or facial discomfort (often caused by muscle contraction induced by the stimulation). Hearing loss,
TMS can be applied to cortical regions beyond the motor cortex, where it can evoke local field potentials and regional brain activation, which can be captured by coupling TMS with other imaging modalities.

transient mood or cognitive changes, and syncope have also been observed but are far less common. The most worrisome consequence of TMS, particularly rTMS, is seizure induction. However, when applied with established safety parameters (e.g., with respect to stimulation intensity and duration), seizures are exceedingly rare. Careful screening of potential recipients of TMS is also important to lower the likelihood of seizure induction. For example, potential recipients should be screened for factors that might lower their seizure threshold (e.g., medications that may be epileptogenic). In the case of pregnancy, it is unlikely that TMS to the scalp would affect the fetus given the rapid rate of attenuation of the magnetic field with distance. However, pregnant women should only receive TMS on a case-by-case basis after a risk-benefit ratio has been assessed, and spinal stimulation should be avoided entirely. Thus, when used within established guidelines, in appropriate patients and in the appropriate setting (e.g., with trained personnel), TMS is considered to be safe.

Established applications of TMS

Presurgical motor mapping As stated above, the US FDA has approved TMS for presurgical motor and language mapping. By taking advantage of stereotactically guided neuronavigation, TMS can target cortical regions defined by the individual’s own brain MRI and thereby systematically probe motor responses, as measured by MEPs induced in different target muscles. As a result, it becomes possible to assess what areas of cortex can be safely excised during tumor resection, or during the removal of an epileptogenic focus, without inducing significant postoperative motor deficits. TMS is able to perform these functions with accuracy profiles similar to those observed with invasive cortical mapping approaches.

Presurgical language mapping The utility of TMS as a means to probe language function dates back to the original demonstration of its ability to induce speech arrest. More recent investigations have directly compared rTMS to intracarotid amobarbital test (Wada test) in determining hemispheric language dominance, with varying results. A recent study assessed language function in 20 neurosurgical patients with left hemispheric lesions via an object naming task. The authors found good concordance between presurgical language mapping with TMS and intraoperative language mapping in awake patients.

Treatment-refractory major depression Repetitively administered TMS, when delivered to the dorsolateral prefrontal cortex (DLPFC), is an established treatment for certain forms of medication-refractory major depressive disorder (MDD). In these cases, rTMS is typically delivered as high-frequency stimulation to left DLPFC or, less commonly, as low-frequency stimulation to right DLPFC over daily sessions. The efficacy of TMS in treating depression has been supported by large randomized, sham-controlled trials and several meta-analyses. While the parameters, location, and duration of stimulation in the treatment of depression have yet to be standardized, TMS systems commonly deliver 10-Hz stimulation in daily sessions, 5 sessions per week over a period of 2–6 weeks. One of the 2 FDA-approved TMS systems utilizes a uniquely configured stimulation coil (H-coil), which enables deeper stimulation of the human brain. Duration of stimulation, efficacy, and side-effect profile appears

Neurology: Clinical Practice | December 2013

© 2013 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
to be similar to that of the more conventional system, though comparative studies or data are not yet available.

Research suggesting potential diagnostic applications of TMS in neurology

TMS can measure corticospinal integrity through the ascertainment of central motor conduction time (CMCT), an index of the time between motor cortex stimulation and the firing of spinal motor neurons (figure 1A). Physiologically, CMCT is typically assessed by subtracting the conduction time between anterior horn cell motor neurons and muscle (i.e., the peripheral conduction time) from the cortical to muscle conduction time. Mechanistically, peripheral conduction time can be assessed in 1 of 2 ways: either by directly stimulating over the spine to activate spinal roots, or by making use of the F wave (the muscle response elicited by antidromically stimulating the anterior horn cell following peripheral nerve stimulation). The formula for calculating peripheral conduction time is then determined as (F wave latency + M wave latency − 1)/2, where the M wave is that elicited from directly stimulating the peripheral nerve. Of the 2 methods for assessing peripheral conduction time, direct spinal stimulation is considered less accurate because of the large degree of variability in the extent to which spinal roots are stimulated (e.g., owing to anatomical variability). Clinically, CMCT could potentially be used to assess the severity of myelopathy in cord compression, the functional level of a cord compression, as a tool to differentiate myelopathy from motor neuron disease, or possibly as a means of predicting functional recovery in MS. Further, because the procedure for estimating CMCT involves single-pulse TMS, it would not be associated with substantial safety concerns.

TMS can be applied to cortical regions beyond the motor cortex, where it can evoke local field potentials and regional brain activation, which can be captured by coupling TMS with
In the case of localization-related epilepsy, TMS can be used to directly target a documented cortical seizure focus, or to stimulate an accessible cortical target connected to a subcortical focus.

Other imaging modalities, such as EEG and functional MRI (fMRI), can be used to assess behavioral effects induced by the stimulation. In this manner, the cognitive impacts from stimulating a particular brain region or brain network can be gauged. For example, as stated above, there is FDA clearance to use TMS as a tool to elaborate language pathways. The use of TMS as a tool to map processing in other cognitive domains, however, remains relegated to research at this time.

Research suggesting potential therapeutic applications of TMS in neurology

While TMS has not been FDA-approved as a treatment modality for neurologic disease, studies are underway to explore the potential therapeutic use of TMS for a diverse array of neurologic disorders. Available evidence of efficacy to date is limited to proof-of-principle studies and often to only acute effects. Larger and better-controlled clinical trials that address the durability of the potential benefits are needed to explore the therapeutic potential of TMS. With respect to the putative durability of any clinical effects, it is anticipated that any efficacious therapeutic application of TMS would require multiple repeated sessions of stimulation, as is the case in the treatment of major depression.

Epilepsy

Some forms of rTMS (e.g., low-frequency, 1-Hz rTMS or continuous theta burst TMS) can suppress cortical excitation and induce LTD-like changes (possibly through GABAergic modulation). Therefore, these have been investigated as an abortive strategy for seizures and can be useful, for example, in focal status epilepticus or epilepsy partialis continua. In the case of localization-related epilepsy, TMS can be used to directly target a documented cortical seizure focus, or to stimulate an accessible cortical target connected to a subcortical focus. However, the antiepileptic efficacy of TMS is closely tied to the relative success of targeting the epileptogenic regions. As such, medial temporal lobe foci are not amenable to TMS treatment with current methods. Reductions in seizure frequency following rTMS have been demonstrated in many but not all randomized sham-controlled trials.

There is currently no FDA approval for the use of TMS in the treatment of epilepsy.

Stroke rehabilitation

Following a stroke, there appears to be a hemispheric imbalance with excessive inhibition from the healthy to the lesioned hemisphere. TMS has been employed either to suppress contralesional cortex (with low-frequency stimulation) or to augment cortical excitability in ipsilateral, perilesional cortex (with high-frequency stimulation). In addition to enhancing motor recovery after stroke, other preliminary studies have shown promising results using similar TMS paradigms to improve aphasia and hemispatial neglect following stroke. Nevertheless, in this context, TMS or other noninvasive techniques such as transcranial direct current stimulation may be most effective when combined with other rehabilitation strategies. Issues surrounding patient characteristics, timing of the TMS intervention, and effective stimulation parameters will need to be determined for both FDA approval and widespread clinical use to treat deficits following stroke.

Movement disorders

There are mounting data from sham-controlled studies to support the use of high-frequency rTMS to premotor and primary motor cortices in improving...
bradykinesia and freezing in Parkinson disease (PD). These effects might be mediated by transsynaptic modulations of the nigrostriatal-thalamocortical circuit.

Low-frequency rTMS aiming to suppress cortical excitability has been applied to similar motor and premotor regions as a way of decreasing L-Dopa–induced dyskinesias with some success, and cerebellar targets are also being explored. TMS has also been investigated as a treatment option in dystonias, with controlled studies demonstrating therapeutic benefits from targeting dominant primary motor cortex (M1) in focal hand dystonia. Multicenter trials are currently underway to better define the effectiveness of TMS for motor symptoms in PD, as a first step toward possible FDA approval.

**Chronic pain** TMS has shown promise in decreasing chronic pain in patients with neuropathic pain (e.g., that resulting from peripheral nerve, spinal cord, or central sensory pathway injury), fibromyalgia, and complex regional pain syndrome. The applicability of TMS to visceral pain (e.g., chronic pancreatitis) has also been reported. Stimulation sites for these studies commonly involve the primary somatomotor cortex (SM1), with the supposition that pain suppression occurs by way of the activation of interconnected thalamic nuclei, and through downstream effects upon brainstem and spinal cord nuclei and interconnected limbic regions. Ongoing studies are aimed at better defining the target of stimulation, the parameters for stimulation, and the patient characteristics that predict response. However, effect sizes in patients who do respond to TMS can be substantial, and duration of benefit clinically significant.

**Tinnitus** Application of rTMS over primary auditory cortex appears to decrease tinnitus, and repeated sessions of rTMS to this region have been shown to induce more persistent suppression of tinnitus in several controlled studies. Most studies have applied low-frequency rTMS, but the optimal parameters are unclear. Furthermore, the effects of rTMS show high degrees of interindividual variability (possibly related to variability in age, hearing loss, and the chronicity of the tinnitus).

**DISCUSSION**

In contrast to other neurostimulation approaches, TMS is noninvasive. Similar to these approaches, TMS is capable of causally assessing brain–behavior relationships, which has clear diagnostic implications for neurologic disorders. Such diagnostic potential has already been realized in the now approved use of TMS for presurgical motor and language mapping. While there are currently no FDA-approved treatment regimens for neurologic disorders, mounting experimental evidence suggests that TMS might offer therapeutic promise for neurologic conditions wherein current treatment options are substantially suboptimal or lacking altogether.

**REFERENCES**


STUDY FUNDING
M. Eldaief was supported by NIH grant 5K23MH099413.

DISCLOSURES
M. Eldaief reports no disclosures. D. Press has received travel and speaker honoraria from Headache Cooperative of Northeast and the Medical School of Singapore; receives publishing royalties from UpToDate; receives approximately 25% of his salary from his role as clinical director for the Center for Noninvasive Brain Stimulation; and receives research support from Fidelity Bioscience Research Initiative and the NIH. A. Pascual-Leone serves on Scientific Advisory Boards for Nexstim, Neosync, Starlab, Neuronix, Allied Minds, and Novavision; serves as Associate Editor for European Journal of Neuroscience and Frontiers in Neuroscience; is listed as coinventor in several patents related to real-time integration of TMS with EEG and functional imaging; and receives research support from Nexstim, Neuronix, the NIH (NEI, National Institute of Neurological Disorders and Stroke, NCRR), Michael J. Fox Foundation, Berenson-Allen Foundation, and RUG Family Foundation. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
### Related articles from other AAN physician and patient resources

<table>
<thead>
<tr>
<th>Source</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Continuum®</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction: The evolving field of neurorehabilitation</td>
<td>June 2011; 443–448.</td>
</tr>
<tr>
<td></td>
<td>Emerging therapies in neurorehabilitation</td>
<td>June 2011; 530–544.</td>
</tr>
<tr>
<td><strong>Neurology Now®</strong></td>
<td>Sounds of silence</td>
<td>February/March 2012; 8:20–25.</td>
</tr>
<tr>
<td></td>
<td>This way in: ADHD causes motor skill problems</td>
<td>June/July 2011; 7:13–14.</td>
</tr>
<tr>
<td><strong>Neurology Today®</strong></td>
<td>In older adults, less frontal volume and slow-wave activity add up to worse memory</td>
<td>March 21, 2013; 13:5–6.</td>
</tr>
</tbody>
</table>